IN last one year equity market has generated huge return for their investors, however, some of them have outperformed by huge margins to the wider market. One of the sectors is pharmaceuticals. After going into a downturn post-pandemic, they have shown a remarkable return in last one year. The Nifty Pharma index have clocked healthy gains, significantly outperforming the equity benchmark Nifty 50. The performance data clearly illustrates the significant outperformance of the Nifty Pharma Index compared to the frontline equity index Nifty 50 across various durations.
Nifty Pharma is consistently demonstrating superior returns. Over one year, for instance, Nifty Pharma surged by an impressive 60.39 per cent, more than doubling the return of the Nifty 50 at 28.30 per cent. Data show that the Nifty Pharma index has gained 24.95 per cent while the Nifty 50 has risen 14.64 per cent in the last six months. If we consider the shorter timeframe, the pharma index has gained by 20.69 per cent in the last three months while the Nifty 50 has gained 12.37 per cent.
This substantial outperformance underscores the strength and resilience of the pharmaceutical sector, likely driven by factors such as innovative drug pipelines, global demand for healthcare, and increased focus on healthcare spending, thereby positioning Nifty Pharma as a standout performer in the equity market landscape.
Why Pharma is at Pink of the Health?
A confluence of factors has played in favour of pharma companies.
continued strength in US Generics Market: The US generics market, the world’s largest and also Indian company’s largest market is expected to maintain steady growth in coming futures due to factors like:
This story is from the March 2024 edition of Indian Economy & Market.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 2024 edition of Indian Economy & Market.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
NEW INVESTMENT PRODUCT CATEGORY IS SEBI'S LATEST MOVE COMMENDABLE?
The Securities and Exchange Board of India (SEBI) has introduced a consultation paper proposing a new investment product category aimed at addressing a specific market need. This proposed asset class would offer investment options that sit between mutual funds (MFS) and PMS, filling a gap and providing greater flexibility in portfolio management. The new investment vehicle is designed for investors who are prepared to take on riskier market positions but find PMS schemes or AIFs out of reach. SEBI after reviewing the feedback and finalizing the regulations through stakeholder discussions, may issue the final regulations.
DECODING THE CHINA MYTH
Myths die hard. Among these is the great myth that China's poised to take over the world. Here, James Rickards debunks that myth.
What Is In Store For The Indian Economy?
Until the 2014 Lok Sabha elections, when the Bharatiya Janata Party secured 282 seats and Narendra Modi ascended to power, India experienced 21 years of coalition governments. A decade later, the BJP holds 240 seats in the Lok Sabha, and India is once again governed by a coalition. Fitch has indicated that coalition politics and a weakened mandate for the NDA could hinder the passage of ambitious reform legislation. It raises the question: Do coalition governments impede the economic reform agenda?
Transforming The Indian Stock Market
With a rising number of millennials, Gen Z investors, and tech-savvy traditional investors, Robo advisors are making a significant impact on the FinTech and WealthTech sectors. Factors like growing per capita income, favourable demographics, and increasing smartphone and internet Usage further enhance India’s potential as a robust market. Al’s role in stock market analysis is unquestionably growing. It enhances rather than replaces human judgment, providing powerful tools for informed investment decisions.
Rudra Global Infra Products Ltd.
READY FOR EXPONENTIAL GROWTH WITH ENTRY INTO AEROSPACE & DEFENCE SECTOR
Dividend Powerhouses Best 5 Stocks for Yield and Growth
Enhance your investment strategy in these volatile times with these highyield dividend stocks known for their strong performance and reliability.
Face to Face
\"We believe ourselves to be service providers and not any goods manufacturer\"
THE REALITY OF CORPORATE ESG INITIATIVES
Today, environmental, social, and governance (ESG) considerations dominate business discussions and have become an integral part of the strategies of many organisations in different industries. While some companies are grappling with these new standards and commitments, others, already aligned with the Sustainable Development Goals (SDGs), are well prepared to meet the evolving regulations and standards related to corporate social responsibility (CSR) and ESG.
Standard Capital Markets Ltd. Incorporates Subsidiary for Insurance Broking
Standard Capital Markets Ltd., a leading player in the financial services sector, has announced that it has incorporated a subsidiary under the name of “Standard Insurance Broking Ltd.” to act as a Direct broker under the Insurance Regulatory and Development Authority of India (Insurance Brokers) Regulations, 2018.NOC of Insurance Regulatory and Development Authority of India already taken and now company will also apply for taking Insurance Broking License of Insurance Regulatory and Development Authority of India (IRDAI).
THE IMMINENT MIDDLE EAST WAR
Recent intelligence from a variety of sources points to an Israeli war against Hezbollah, which is an Iranian proxy. Hezbollah is systematically attacking Israeli bases, radars, intelligence-collections facilities and other defense system components. Now the attacks are spreading to include Israeli settlements in the West Bank and Galilee. You’re just not hearing about it in the mainstream media. These attacks have three effects: They break down Israeli military and intelligence systems, terrorize the civilian population and handicap Israel’s ability to conduct air attacks on Syria or Lebanon. James Rickards points out why all these are imminent.